Aeglea BioTherapeutics, Inc. (AGLE)
Market Cap | 48.45M |
Revenue (ttm) | 1.23M |
Net Income (ttm) | -272.56M |
Shares Out | 4.05M |
EPS (ttm) | -71.00 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,974 |
Open | 11.78 |
Previous Close | 11.86 |
Day's Range | 11.78 - 12.17 |
52-Week Range | 2.66 - 39.00 |
Beta | 2.53 |
Analysts | Hold |
Price Target | 20.00 (+64.34%) |
Earnings Date | Nov 2, 2023 |
About AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline inclu... [Read more]
Financial Performance
In 2022, AGLE's revenue was $2.33 million, a decrease of -87.57% compared to the previous year's $18.74 million. Losses were -$83.82 million, 27.4% more than in 2021.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for AGLE stock is "Hold." The 12-month stock price forecast is $20.0, which is an increase of 64.34% from the latest price.
News

Aeglea BioTherapeutics to Participate in Upcoming September Conference
WALTHAM, Mass. , Sept. 14, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to tran...

Aeglea BioTherapeutics Announces Reverse Stock Split
WALTHAM, Mass. , Sept. 7, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to trans...

Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
Scott Burrows, former Arcutis Biotherapeutics CFO, assumes role as Chief Financial Officer Heidy Abreu King-Jones, former Provention Bio CLO & Corporate Secretary, assumes role as Chief Legal Officer...

Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
Acquisition of Spyre's assets and concurrent oversubscribed $210.0 million private investment positions the company to advance a potentially best-in-class inflammatory bowel disease (IBD) portfolio, i...

Polar Capital Holdings Plc Enters Stake in Aeglea BioTherapeutics Inc
On July 19, 2023, Polar Capital Holdings Plc (Trades, Portfolio), a London-based investment firm, made a significant move in the biotechnology sector by investing in 3,936,198 shares in Aeglea BioTher...

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma
Global rights to pegzilarginase in development for Arginase 1 Deficiency sold to Immedica Pharma for $15 million upfront cash proceeds and up to $100 million of contingent milestone payments Marketing...

Aeglea BioTherapeutics Announces Grant of Inducement Awards
AUSTIN, Texas and WALTHAM, Mass. , June 23, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE) today announced that, in connection with the acquisition of Spyre Therapeutics, ...

Aeglea BioTherapeutics Announces Acquisition of Spyre Therapeutics
Acquisition of Spyre and concurrent oversubscribed $210 million private investment positions the company to advance a leading inflammatory bowel disease (IBD) portfolio Spyre, the second spinout from ...

Aeglea BioTherapeutics Reports First Quarter 2023 Financial Results
$39.8 million of cash and cash equivalents, marketable securities, and restricted cash as of March 31, 2023 AUSTIN, Texas , May 11, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) toda...

Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas , March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative...

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates
Jeffrey Goldberg, experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 mil...

Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill, M.B.A., has been promoted to the newly created role of...

Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
AUSTIN, Texas, Dec. 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative so...

Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer
AUSTIN, Texas , Nov. 30, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative ...

Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer
AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative...

Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
Interim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 at 1.35 mg/kg MAA for Pegzilarginase for the Treatment of Arginase 1 Deficienc...

Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential Role in Treatment
Event to be Held Thursday, October 27 th at 10 AM ET AUSTIN, Texas , Oct. 19, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new ...

Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program
AUSTIN, Texas , Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative s...

Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2022
AUSTIN, Texas , Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit pe...

Paltalk And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones tumbled by over 500 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
Prioritizing Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 Dr. Anthony Quinn, President, CEO an...

Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegzilarginase for the Treatment of Arginase 1 Deficiency
AUSTIN, Texas , Aug. 18, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peo...

Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forward for Pegzilarginase Gross Proceeds of $45 Millio...

Aeglea BioTherapeutics Shares Plummet Following Refusal To File Letter From FDA
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) announced the U.S. Food and Drug Administration (FDA) has refused to accept the company's Biologics License Application (BLA) with a Refusal to File (RTF) l...

Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peo...